Huntington's Disease News and Research RSS Feed - Huntington's Disease News and Research

Huntington's disease (HD) results from genetically programmed degeneration of brain cells, called neurons, in certain areas of the brain. This degeneration causes uncontrolled movements, loss of intellectual faculties, and emotional disturbance. HD is a familial disease, passed from parent to child through a mutation in the normal gene. Each child of an HD parent has a 50-50 chance of inheriting the HD gene. If a child does not inherit the HD gene, he or she will not develop the disease and cannot pass it to subsequent generations. A person who inherits the HD gene will sooner or later develop the disease. Whether one child inherits the gene has no bearing on whether others will or will not inherit the gene. Some early symptoms of HD are mood swings, depression, irritability or trouble driving, learning new things, remembering a fact, or making a decision. As the disease progresses, concentration on intellectual tasks becomes increasingly difficult and the patient may have difficulty feeding himself or herself and swallowing. The rate of disease progression and the age of onset vary from person to person. A genetic test, coupled with a complete medical history and neurological and laboratory tests, helps physicians diagnose HD. Presymptomic testing is available for individuals who are at risk for carrying the HD gene. In 1 to 3 percent of individuals with HD, no family history of HD can be found.
American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

American Migraine Foundation plans to create Migraine Patient Registry and Biorepository

Migraine affects 36 million Americans, can have a major impact on patients' quality of life, and even on their relationships. The World Health Organization estimates that migraine is the third most prevalent medical disorder in the world, the 4th most disabling among women and the 7th most disabling overall. [More]
Research findings could lead to new drug design for neurological diseases

Research findings could lead to new drug design for neurological diseases

A new intermediate step and unexpected enzymatic activity in a metabolic pathway in the body, which could lead to new drug design for psychiatric and neurodegenerative diseases, has been discovered by researchers at Georgia State University. [More]
Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

An early study suggests that a synthetic triglyceride oil called triheptanoin may provide hope for people with Huntington's disease. The study is published in the January 7, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
New findings may lay groundwork of novel treatment for people with Huntington's disease

New findings may lay groundwork of novel treatment for people with Huntington's disease

By adjusting the levels of a key signaling protein, researchers improved motor function and brain abnormalities in experimental animals with a form of Huntington's disease, a severe neurodegenerative disorder. [More]
Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Offspring of mice treated with drug had delayed onset, reduced symptoms of Huntington's disease

Famine, drug abuse and even stress can "silence" certain genes, causing health problems in generations to come. Now scientists are wondering—could therapies that change gene expression in parents help their children? [More]
VirtualScopics signs software licence, support agreement with IXICO

VirtualScopics signs software licence, support agreement with IXICO

VirtualScopics, Inc., a leading provider of clinical trial imaging solutions, today announced that they have signed a multi-year software licence and support agreement with existing alliance partner, IXICO plc, the brain health company, for their proprietary imaging data and query management digital platform, TrialTracker™. [More]
Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex, Inc. today announced the successful completion of a multicenter Phase 1, multiple ascending dose clinical trial of VX15/2503 anti-Semaphorin 4D (SEMA4D) antibody in 42 adult patients with advanced, refractory solid tumors. [More]
BUSM's Carmela Abraham receives 2014 Massachusetts Neuroscience Consortium Award

BUSM's Carmela Abraham receives 2014 Massachusetts Neuroscience Consortium Award

Carmela Abraham, PhD, professor of biochemistry and pharmacology at Boston University School of Medicine, was one of six recipients of this year's Massachusetts Neuroscience Consortium Award out of nearly 60 applicants. The grant was awarded to her for her work on multiple sclerosis and the role of the life extension protein Klotho in the limited repair of white matter in the disease. [More]
Researchers remake brain and gut stem cells to study potential therapies for fatal diseases

Researchers remake brain and gut stem cells to study potential therapies for fatal diseases

Research scientists have developed a novel method to re-create brain and intestinal stem cells from patients who died decades ago, using DNA from stored blood samples to study the potential causes of debilitating illnesses such as inflammatory bowel disease. [More]
Tufts University study explores relationship between transcription, expansions of DNA repeats

Tufts University study explores relationship between transcription, expansions of DNA repeats

Researchers in human genetics have known that long nucleotide repeats in DNA lead to instability of the genome and ultimately to human hereditary diseases such Freidreich's ataxia and Huntington's disease. [More]
Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Prana Biotechnology has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world’s leading medical journals, The Lancet Neurology. [More]
TSRI scientists discover signaling pathway that contribute to Huntington's disease

TSRI scientists discover signaling pathway that contribute to Huntington's disease

Scientists from the Florida campus of The Scripps Research Institute have uncovered a major contributor to Huntington's disease, a devastating progressive neurological condition that produces involuntary movements, emotional disturbance and cognitive impairment. [More]
Longer looks: Obamacare in the midterm campaign; watching Ebola mutate; lessons on dying

Longer looks: Obamacare in the midterm campaign; watching Ebola mutate; lessons on dying

According to Kantar Media, a firm that tracks political advertising, health care is the main subject of campaign ads, especially Republican ones. Obamacare is unpopular-;over half of Americans disapprove of it. Republicans talk about it constantly on the campaign trail, though not as intemperately as they did during their own party's primaries. Democrats scarcely mention it (10/18). [More]
Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros Corporation today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. [More]
Researchers discover mechanism that leads to generation of new nerve cells after stroke

Researchers discover mechanism that leads to generation of new nerve cells after stroke

A previously unknown mechanism through which the brain produces new nerve cells after a stroke has been discovered at Lund University and Karolinska Institutet in Sweden. The findings have been published in the journal SCIENCE. [More]
Six research institutions awarded NIH grants to create database of human cellular responses

Six research institutions awarded NIH grants to create database of human cellular responses

Building on a successful three-year pilot project, the National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures. [More]
Scientists apply iPS cell technology to Huntington's disease transgenic monkey model

Scientists apply iPS cell technology to Huntington's disease transgenic monkey model

Creating induced pluripotent stem cells or iPS cells allows researchers to establish "disease in a dish" models of conditions ranging from Alzheimer's disease to diabetes. [More]
Prana's PBT2 receives FDA Orphan Drug designation for treatment of Huntington disease

Prana's PBT2 receives FDA Orphan Drug designation for treatment of Huntington disease

Prana Biotechnology has today announced the US Food and Drug Administration has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease. [More]
New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy. [More]
Huntingtin protein plays critical role in long-term memory development

Huntingtin protein plays critical role in long-term memory development

It has been more than 20 years since scientists discovered that mutations in the gene huntingtin cause the devastating progressive neurological condition Huntington's disease, which involves involuntary movements, emotional disturbance and cognitive impairment. [More]